Table 1.
Demographics of Participants in the A5321 Hair Study (n = 110)
| Participant Characteristic | N or Median (%, range or IQR) |
|---|---|
| Age at study entry (years) | 48 (range 23–69) |
| Sex | |
| Male | 84 (76%) |
| Female | 26 (24%) |
| Race/ethnicity | |
| White non-Hispanic | 65 (59%) |
| Black non-Hispanic | 17 (15%) |
| Hispanic | 25 (23%) |
| Asian/Pacific Islander | 3 (3%) |
| Years of ART at study entry | 7 (range 4–16) |
| CD4+ cell count (cells/mm3) | |
| Pre-ART | 250 (IQR, 101–359) |
| Study entry | 661 (IQR, 494–839) |
| Pre-ART plasma HIV-1 RNA (log10cps/mL) | 4.6 (IQR, 4.2–5.1) |
| ART regimen at A5321 entry (all TDF-FTC based) | 46 (42%) EFV; 7 (6%) RPV; 1 (1%) NVP; 11 (10%) ATV/r; 18 (16%) DRV/r; 5 (5%) EVG/cobi; 22 (20%) RAL |
| Measures of viral persistence | |
| Plasma HIV-1 RNA (iSCA, copies/mL) | 52% < 0.4; 48% ≥ 0.4 |
| Cell associated HIV-1 RNA (copies/106 CD4+ cells) | 48 (IQR, 14–142) |
| Cell associated HIV-1 DNA (copies/106 CD4+ cells) | 564 (IQR, 229–1236) |
Abbreviations: ART, antiretroviral therapy; ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; EFV, efavirenz; EVG/cobi, elvitegravir/cobicistat; IQR, interquartile range; iSCA, single copy assay; NVP, nevirapine; RPV, rilpivirine.